Literature DB >> 16181536

[Effect of compound recipe Gengniankang on senile sexual hormone and expression of estrogen receptor in bone of climacteric female rats].

Su-hui Wu1, Jing-fen Sun, Shu-zhen Guo.   

Abstract

OBJECTIVE: To compare the therapeutic effect of Compound Recipe Gengniankang ( GNK) with that of hormone replacement treatment (HRT) on climacteric female rats with osteoporosis, and to investigate the roles of estrogen and estrogen receptors in the mechanism of osteoporosis.
METHODS: Climacteric female rats with osteoporosis were chosen and divided into three groups (GNK group, HRT group and control group). Apoptosis of ovarian granulose cells was measured by terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL) assay. Serum level of estradiol (E(2)), follicle stimulating hormone (FSH), luteinizing hormone (LH) were determined by the method of radioimmunoassay (RIA). Reverse transcriptase polymerase chain reaction (RT-PCT) technology was used to evaluate the expression of estrogen receptor (ER) in bone. Bone mineral density (BMD) was measured by double energy X-ray absorption (DEXA).
RESULTS: In the climacteric rats, BMD, serum E(2), ER mRNA expression in bone decreased remarkably, and serum FSH, LH and apoptosis of ovarian granulose cells increased obviously. After treating with GNK, all the indexes were reversed except serum E(2). The increase of E(2) was not significant.
CONCLUSION: GNK is effective on climacteric osteoporosis female rats. Its role is performed not by increasing serum E(2) but by enhancing ER in the bone and inhibiting apoptosis of ovarian granulose cells. GNK can deter further exhaustion of ovarian function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181536     DOI: 10.1007/bf02836506

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  10 in total

Review 1.  [Phytoestrogens and SERMS, alternatives to classical hormone therapy?].

Authors:  J Huber
Journal:  Ther Umsch       Date:  2000-10

Review 2.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

Authors:  B Lawrence Riggs; Lynn C Hartmann
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

3.  ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2002-12       Impact factor: 3.561

Review 4.  Selective estrogen receptor modulators: tissue actions and potential for CNS protection.

Authors:  M T Littleton-Kearney; N L Ostrowski; D A Cox; M I Rossberg; P D Hurn
Journal:  CNS Drug Rev       Date:  2002

5.  HRT and SERMs: the good, the bad...and the lovely?

Authors:  Kathryn Sandberg
Journal:  Trends Endocrinol Metab       Date:  2002-10       Impact factor: 12.015

Review 6.  Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis.

Authors:  C R Sirtori
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

Authors:  M Dowsett; N J Bundred; A Decensi; R C Sainsbury; Y Lu; M J Hills; F J Cohen; P Veronesi; M E O'Brien; T Scott; D B Muchmore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-09       Impact factor: 4.254

8.  Serum estradiol level and risk of breast cancer during treatment with raloxifene.

Authors:  Steven R Cummings; Tu Duong; Emily Kenyon; Jane A Cauley; Malcolm Whitehead; Kathryn A Krueger
Journal:  JAMA       Date:  2002-01-09       Impact factor: 56.272

9.  Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study.

Authors:  Steven R Goldstein; Nayan Nanavati
Journal:  Am J Obstet Gynecol       Date:  2002-09       Impact factor: 8.661

Review 10.  [Specific estrogen receptor modulators (SERMs)].

Authors:  Florence Trémollières; Patrice Lopes
Journal:  Presse Med       Date:  2002-09-07       Impact factor: 1.228

  10 in total
  3 in total

1.  Combining ZHENG Theory and High-Throughput Expression Data to Predict New Effects of Chinese Herbal Formulae.

Authors:  Shuhao Yu; Zhizhong Guo; Yan Guan; Yi-Yu Lu; Pei Hao; Yixue Li; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-14       Impact factor: 2.629

2.  Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.

Authors:  Ji-Ming Chen; Hong-Yan Gao; Yi Ding; Xia Yuan; Qing Wang; Qin Li; Guo-Hua Jiang
Journal:  Chin Med J (Engl)       Date:  2015-02-20       Impact factor: 2.628

Review 3.  Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis.

Authors:  Weiping Liu; Truong-Nam Nguyen; Thu-Van Tran Thi; Shaohu Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2019-06-26       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.